1. Home
  2. COUR vs XERS Comparison

COUR vs XERS Comparison

Compare COUR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coursera Inc.

COUR

Coursera Inc.

HOLD

Current Price

$6.04

Market Cap

1.0B

Sector

Technology

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$5.46

Market Cap

965.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COUR
XERS
Founded
2012
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
965.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
COUR
XERS
Price
$6.04
$5.46
Analyst Decision
Buy
Strong Buy
Analyst Count
14
7
Target Price
$11.07
$10.43
AVG Volume (30 Days)
5.0M
2.1M
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
39.22
100.00
EPS
N/A
N/A
Revenue
$757,500,000.00
$49,590,000.00
Revenue This Year
$9.34
$28.65
Revenue Next Year
$6.60
$18.33
P/E Ratio
N/A
N/A
Revenue Growth
9.04
142.67
52 Week Low
$5.47
$3.81
52 Week High
$13.56
$10.08

Technical Indicators

Market Signals
Indicator
COUR
XERS
Relative Strength Index (RSI) 43.89 26.31
Support Level $5.47 $4.30
Resistance Level $6.38 $5.49
Average True Range (ATR) 0.29 0.34
MACD -0.01 -0.06
Stochastic Oscillator 17.10 3.62

Price Performance

Historical Comparison
COUR
XERS

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: